#8
CRISPR-Cas9 Gene Editing (Doudna and Charpentier, 2012)
2012 discovery enables cut-and-paste DNA editing. FDA approved first CRISPR cure in 2023.
CRISPR-Cas9 gene editing provides a programmable tool to cut DNA with precision, enabling cures for genetic diseases. In 2012, Doudna and Charpentier showed Cas9 could target any sequence using guide RNA. The FDA approved Casgevy in 2023 as the first CRISPR therapy for sickle cell disease, costing $2.2 million per patient. Clinical trials target cancer and HIV. Doudna and Charpentier won the 2020 Nobel Prize in Chemistry.
Photos (1)
Comments on "CRISPR-Cas9 Gene Editing (Doudna and Charpentier, 2012)"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.